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proliferation in breast cancer cells
Sofia Winslow1, Karin Leandersson2 and Christer Larsson1*Abstract
Background: Regulation of mRNAs is one way to control protein levels and thereby important cellular processes such
as growth, invasion and apoptosis. G3BPs constitute a family of mRNA-binding proteins, shown to be overexpressed in
several cancer types, including breast, colon and pancreas cancer. G3BP has been reported to both stabilize and induce
degradation of specific mRNAs.
Results: Here, we show that G3BP1, but not G3BP2, supports proliferation of several breast cancer cell lines. Global gene
expression analyses of G3BP1- and G3BP2-depleted cells indicate that primarily G3BP1, and much less G3BP2, influences
mRNA expression levels. Peripheral myelin protein 22 (PMP22) was one gene that was significantly influenced by G3BP1
depletion which led to a 2–3 fold increased expression. Depletion of PMP22 resulted in increased proliferation and the
G3BP1-mediated effect on proliferation was not seen upon PMP22-depletion.
Conclusions: This indicates a novel role for G3BP1 in the regulation of cell proliferation in breast cancer cells, perhaps
via a regulatory effect on PMP22 expression.
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Regulation of mRNA levels and mRNA translation is im-
portant since these processes to a large extent determine
protein expression [1]. Regulation of mRNAs is frequently
mediated by factors binding to AU-rich elements (ARE) in
the 3’UTR [2]. Ras-GTPase activating protein SH3 domain
binding proteins (G3BPs) constitute one group of such
mRNA-binding proteins and consist of a family of three
homologous proteins (G3BP1, G3BP2a and G3BP2b) [3].
The name originates from early reports of G3BP1 interact-
ing with the SH3 domain of RasGAP [4], even though
more recent studies have questioned this finding [5]. All
G3BP proteins contain a RNA recognition motif (RRM)
and have been shown to have both mRNA-stabilizing
effects, exemplified by TAU mRNA [6] as well as mRNA-
degrading effects, as demonstrated for c-MYC [7], BART
[8], CTNNB1 [9], ATP5B [10], IGF-II, and GAS5 [11].The
degrading effect has been indicated to be mediated by
endonuclease activity of the G3BPs themselves [12].* Correspondence: Christer.Larsson@med.lu.se
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have been shown to be important for regulation of pro-
cesses that can influence cancer, such as cell growth and
motility [7,8]. Overexpression of G3BP1 can promote S-
phase entry in a RNA-binding domain-dependent way in
fibroblasts [13] and up-regulation of G3BP1 has been de-
tected in proliferating retinal pigment epithelial cells [14].
A potential role for G3BPs in cancer is indicated by the
finding that they have been found to be expressed at high
levels in many different tumor types e.g. breast [13,15,16],
pancreas [8], thyroid, colon, head and neck tumors [13] as
well as in several cancer cell lines [8,13].
The aim of this study was to investigate a putative role
for G3BPs in breast cancer cell growth. G3BP1 and/or
G3BP2 were depleted and the effects on cell growth and
global gene expression were analyzed. We found that
G3BP1 to a larger extent than G3BP2 influences mRNA
expression levels and breast cancer cell proliferation.
Peripheral myelin protein 22, PMP22, was one gene that
was influenced by G3BP1 levels and potentially mediates
the G3BP1 effect on cell proliferation.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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G3BP1 depletion decreases cell proliferation
To elucidate the role of G3BP proteins in breast cancer
cell growth, we analyzed the effects of G3BP depletion
on cell proliferation and death. Significant reduction in
proliferation, measured as [3H]-thymidine incorporation,
was detected following G3BP1 depletion in MCF-7, MDA-
MB-468 and BT549 cells (Figure 1A, C and D). The same
tendency, but not significant, was seen in MDA-MB-231
cells (Figure 1B). Knockdown of G3BP2 did not lead to re-
duced proliferation. Three separate G3BP1 siRNAs all had
the same effect (Figure 1E) making it unlikely that it is a
consequence of off-target effects. None of three G3BP2
siRNAs had a suppressive effect on MCF-7 cell prolifera-
tion (Figure 1F). Normalization to protein content was
also done. In this case siG3BP1 led to a [3H]-thymidine in-
corporation per cellular protein of 62.2 ± 7.9% (mean ±
SEM, n = 4) compared to control cells. The effect can
therefore conceivably not be explained by fewer cells, but
is more likely due to lower incorporation rate per cell.
In addition, the total number of viable cells was quan-
tified after 96 hours in culture in the presence of siRNAs
targeting G3BP1 and/or G3BP2 (Figure 1G and H).
For both MCF-7 and MDA-MB-468 cells, depletion of
G3BP1 +G3BP2 led to reduced number of cells. Targeting
only G3BP1 led to a significant reduction of MDA-MB-
468 cells and a tendency to lower MCF-7 cell number.
Downregulation of G3BPs in MCF-7 cells was confirmed
by Western blot (Figure 1I-K). Thus, G3BP1, but not
G3BP2, seems to be a proliferation-promoting factor in
breast cancer cells.
G3BP-depletion does not influence cell death in breast
cancer cell lines
Since G3BP1 has been reported to be a pro-survival factor
[11], we evaluated if depletion of G3BPs can affect cell
survival in breast cancer cells. Knockdown of G3BPs did
not influence cell death, measured as Annexin V positiv-
ity, in MCF-7 (Figure 2A) or MDA-MB-468 (Figure 2B)
cells. Because of the high percentage of Annexin V posi-
tive cells under control conditions, we also quantified the
number of nuclei with apoptotic morphology (Figure 2C
and D). The effect was the same as was seen in the
Annexin V assay, no G3BP siRNA influenced the number
of apoptotic nuclei. However, the basal rate was much
lower compared with the Annexin V data (1-2% apoptotic
nuclei vs approximately 30% Annexin V-positive cells).
This is conceivably due to the fact that floating cells are
included in the Annexin V assay, thereby yielding a meas-
ure of accumulated cell death. For the nuclear morph-
ology analysis, only cells that still are attached to the dish
will be analysed, thus giving a measure of the fraction of
cells that are currently undergoing certain steps in theapoptotic process. Taken together, the data indicate that
neither protein is important for MCF-7 or MDA-MB-468
cell survival.Gene expression profiling indicates different roles for
G3BP1 and G3BP2 in breast cancer cells
G3BPs are considered to be RNA-binding proteins. To
analyze whether altered mRNA expression may be in-
volved in the effects of G3BP knockdown seen on cell
proliferation, global gene expression in G3BP1- and/or
G3BP2-depleted MCF-7 breast cancer cells was analyzed
with microarray. Clustering of the expression data re-
vealed that control cells and siG3BP2-treated cells largely
clustered together (Additional file 1: Figure S1). Only one
control sample diverged from this pattern. Likewise, cells
treated with siG3BP1 or the combination of siG3BP1 and
siG3BP2 oligonucleotides co-clustered, except for one
siG3BP1 sample. The pattern was also seen when the
expression levels of individual genes were compared
(Additional file 2: Table S1). No genes were found to be
significantly altered by downregulation of G3BP2. On
the other hand, downregulation of G3BP1 led to alter-
ations in the expression of several genes. The effect of
siG3BP1 was seen both when it was used as a single
agent and when it was added together with siG3BP2.
This suggests that G3BP1 and G3BP2 differ in their ef-
fects on mRNA expression pattern. G3BP2 only seems
to have minor effects on mRNA levels.G3BP1 suppresses PMP22 mRNA expression
To confirm that the changes observed in the microarray
analysis are due to G3BP1 depletion, qPCR analyses
of the individual genes that were affected (TGFBI,
TNFAIP8, CABLES1, TTC12, PMP22, SCAMP3, ARH-
GEF2, TNFSF10) were performed following treatment
with three separate siG3BP1 oligonuclotides. For one of
the genes, PMP22, the pattern observed in the micro-
array was replicated in the qPCR analyses (Figure 3A)
and was seen for all three G3BP1 siRNAs (Figure 3B).
For the other genes investigated, evaluation with qPCR
showed no consistent effect when other G3BP1 siRNAs
were tested (not shown) which made us exclude them
for further analysis. In contrast to siG3BP1, siG3BP2
treatment had no major effect on PMP22 mRNA levels.
To analyze whether the effect on PMP22 mRNA is
seen in other breast cancer cells as well, three additional
cell lines (MDA-MB-231, MDA-MB-468 and BT549)
were treated with siRNAs targeting G3BP1 and/or
G3BP2 (Figure 3C-E). Knockdown of G3BP1 alone or in
combination with G3BP2-depletion lead to a significant
increase in PMP22 mRNA levels in all cells.
Several efforts were made to analyze PMP22 protein













































































































































































Figure 1 G3BP1 depletion decreases cell proliferation. Breast cancer cell lines MCF-7 (A, E, F), MDA-MB-231 (B), MDA-MB-468 (C) and BT549
(D) cells were transiently transfected with 40 nM siRNA targeting G3BP1 and/or G3BP2 for 72 hours prior to [3H]-thymidine incubation for 6 hours.
Number of MCF-7 (G) and MDA-MB-468 (H) cells was analyzed after transfection with siRNA targeting G3BP1 and/or G3BP2 for 96 hours by
counting viable cells, identified by trypan blue exclusion. Data (mean ± SEM, n = 3) are expressed as [3H]-thymidine incorporation (A-F) and as
total number of viable cells (G-H) related to control cells. * < 0.05, ** < 0.01, *** < 0.001 according to ANOVA followed by Duncan’s multiple range
test. Western blots demonstrate downregulation of G3BPs by their cognate siRNAs (I-K).








































































Figure 2 G3BP1 depletion does not affect cell death. Annexin V-APC staining was performed on G3BP1- and/or G3BP2-depleted MCF-7 (A) or
MDA-MB-468 (B) cells, and analyzed with flow cytometry. Data (mean ± SEM) represent the percentage of Annexin V-positive cells in two (A) or
three (B) independent experiments. Fragmented nuclei were quantified following DAPI-staining of MCF-7 (C) and MDA-MB-468 (D) cells after
G3BP1 and/or G3BP2 depletion. Data are percentage fragmented nuclei (mean ± SEM, n = 3).
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to detection of specific bands in Western blot analyses.Knockdown of G3BP does not influence the mRNA
stability of PMP22
Since G3BP1 is an mRNA-binding protein, a potential
mechanism mediating its effect on mRNA levels could
be through stabilization or destabilization of its targets
[7-11]. To investigate whether this may explain its effect
on PMP22 mRNA levels, G3BP-depleted MCF-7 cells
were treated with actinomycin D for various time pe-
riods to block transcription. Calculations of the half-life
of PMP22 mRNA in three independent experiments in-
dicate no significant changes in PMP22 mRNA stability
after knockdown of G3BPs (Table 1). The results suggestthat G3BP1 does not suppress PMP22 mRNA levels by
influencing its stability in MCF-7 cells.
G3BP increases cell proliferation
We next analyzed whether increasing the G3BP levels
could further increase the proliferation rate. MCF-7
cells were transiently transfected with vectors encoding
FLAG-tagged G3BP1, G3BP2a and G3BP2b. G3BP2a
and G3BP2b are G3BP2 isoforms generated by alternate
splicing. Overexpression of G3BP1 or G3BP2b led to
significantly increased proliferation (Figure 4A). In the
same line, G3BP2b overexpression induced a significant
downregulation of PMP22 mRNA levels and a similar
tendency could also be observed upon increased G3BP1
levels (Figure 4B). G3BP overexpression was confirmed









































































































































Figure 3 G3BP1 depletion increases PMP22 mRNA expression. PMP22 mRNA levels were analyzed with qPCR in MCF-7 (A), MDA-MB-231 (C),
MDA-MB-468 (D) or BT549 (E) cells treated with 40 nM siRNA targeting G3BP1 and/or G3BP2 for 72 hours. (B) MCF-7 cells were treated with three
separate G3BP1 siRNAs and PMP22 mRNA levels were analyzed. Data (mean ± SEM, n = 3) were normalized to three house-keeping genes SDHA,
YWHAZ and UBC and related to levels in cells transfected with control siRNA. * < 0.05; ** < 0.01; *** < 0.001 according to ANOVA followed by
Duncan’s multiple range test.
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PMP22 (peripheral myelin protein 22) was first identi-
fied as a growth-arrest-specific gene (Gas3) [17,18]. It is
therefore possible that the increase in PMP22 following
G3BP1 downregulation, may be a mediator of the sup-
pressed proliferation seen under this condition. PMP22
was therefore downregulated in MCF-7 cells (Figure 5A)
which resulted in increased proliferation. Efficiency of
PMP22 siRNA was evaluated with qPCR (Figure 5B).
Concomitant downregulation of PMP22 partially reversed
the decreased proliferation seen by siG3BP1 alone in
MCF-7 cells (Figure 5C). In MDA-MB-231 cells no effect
of siG3BP1 could be seen in the presence of siPMP22Table 1 Determination of PMP22 mRNA stability in
G3BP-depleted cells after actinomycin D treatment
SiRNA PMP22 t1/2 (h)
(Mean ± SEM, n = 3)
SiCtrl 4.4 ± 0.67
SiG3BP1 4.2 ± 0.09
SiG3BP2 3.9 ± 0.26
SiG3BP1/2 4.3 ± 0.48(Figure 5D). The basal PMP22 levels are substantially
higher in MDA-MB-231 cells (Figure 5E) which may ex-
plain the differences between the cell lines in terms of
siPMP22 effect. Together the data is in line with a hypoth-
esis that PMP22 could be one mechanism of importance
for G3BP1-mediated cell growth regulation.
Discussion
Functional studies of G3BPs have indicated a role for
these RNA-binding proteins in cell growth. Here we
show that G3BP1 is important for optimal breast cancer
cell proliferation. This is in line with findings that down-
regulated levels of G3BP1 lead to suppressed growth in
colon carcinoma cells [19] and that mice with G3BP1
gene deletion have decreased fetal growth and higher
embryonic lethality [11]. However, we could not find any
evidence for a survival role for G3BP1 as has been sug-
gested in the same studies. In concordance with the ef-
fect on cell growth, G3BP1 [8,13,15], but also G3BP2
[16] has been reported to be up-regulated in various
tumor types and higher levels of G3BP1 have been re-
ported in proliferating retinal epithelial cells [14]. We

































































Figure 4 G3BP1 increases cell proliferation. MCF-7 cells were transiently transfected with expression vectors encoding FLAG-tagged G3BP1,
G3BP2a or G3BP2b for 24 hours (A, B) prior to [3H]-thymidine incubation for 6 hours or qPCR analysis. Western blot confirms G3BP overexpression
(C). Data (mean ± SEM, n = 3) are expressed as CPM relative to control. qPCR data (mean ± SEM, n = 3) of PMP22 expression were normalized to












































































































Figure 5 Suppression of PMP22 enhances proliferation. MCF-7 and MDA-MB-231 cells were transiently transfected with siRNA targeting
PMP22 (A-B) or PMP22 and G3BP1 (C-D) prior to [3H]-thymidine incubation (A and C-D) or qPCR analysis (B). Basal PMP22 expression levels were
analysed in MCF-7 and MDA-MB-231 cells using qPCR (E). Data (mean ± SEM, n = 3) are expressed as CPM relative to control. qPCR data (mean ± SEM,
n = 3) of PMP22 expression were normalized to three house-keeping genes SDHA, YWHAZ and UBC and related to control sample. * < 0.05, ** < 0.01,
*** < 0,001, according to ANOVA followed by Duncan’s multiple range test.
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G3BP1 and G3BP2 may have different functions in
breast cancer cells.
G3BP1 and G3BP2 have around 70% sequence similar-
ity [20], suggesting they may have similar functions. Both
G3BP1 and G3BP2 promote stress granule assembly
[21,22] and interact with protein kinase Cα [23] and
both G3BPs have RNA-binding motifs. However, effects
on post-transcriptional regulation has this far only been
reported for G3BP1 [7-12]. In most cases this results in
downregulation of the target mRNAs, except for TAU
which was reported to be stabilized by G3BP1 [6]. None
of the reported G3BP1 targets were significantly altered
in our global gene expression analysis, suggesting that
the effects may depend on cellular context.
So far little is known about G3BP2 effects on gene ex-
pression. Our gene expression data indicate that G3BP1,
but not G3BP2, influences mRNA levels. Thus, both
proliferation and levels of mRNAs are primarily influ-
enced by G3BP1 and not by G3BP2. There are not many
other reports demonstrating differences between G3BP1
and G3BP2. However, there may be subtle differences in
their subcellular localization. Although both proteins are
primarily cytosolic, G3BP2 can localize to the nucleus
after serum stimulation [16] whereas G3BP1 can be
found in the nucleus of quiescent cells as well [7,12].
The fact that G3BP1-specific effects on expression
levels of mRNAs, as assayed by a global analysis, paral-
lels effects on cell proliferation raises the hypothesis that
some of the affected mRNAs may mediate the effects of
G3BP1 on proliferation.
In this study we identified PMP22 mRNA levels as being
influenced by G3BP1 in breast cancer cell lines. PMP22 is
a 22 kDa transmembrane glycoprotein first identified as a
growth arrest specific gene (Gas3). The protein is a major
component of myelin [24] and has been associated with
demyelinating neuropathies [25-28]. However, there are
also reports connecting PMP22 to cancer. For instance,
the PMP22 gene was found to be amplified in two glio-
blastoma cell lines and an unusual transcript was found in
the cells [29], PMP22 mRNA was higher in pancreatic
adenocarcinomas than in normal tissue and was detected
in cell lines [30], and high PMP22mRNA in tumors corre-
lated to poorer survival of breast cancer patients [31].
When it comes to cellular effects, mRNA expression has
primarily been shown to be inversely correlated to cell
growth [18,32-34] and overexpression of PMP22 leads to
delayed G0/G1 to S-phase transition in Schwann cells
[35]. Here, we show that PMP22 depletion results in in-
creased proliferation in breast cancer cells, which supports
the role of PMP22 as a growth arrest-specific gene. The
effect on proliferation by PMP22 is also in line with a hy-
pothesis that decreased PMP22 levels may mediate
G3BP1-promoting effects on proliferation.PMP22 has been reported to be post-transcriptionally
regulated in the 3’UTR in Schwann cells by miRNA [36]
and G3BP1 has been shown to affect mRNA levels by
regulating their stability. However, our results with acti-
nomycin D indicate no variation in stability of PMP22
mRNA in G3BP-depleted cells compared to control
siRNA. The effect on PMP22 mRNA levels may there-
fore be due to a more indirect effect on transcriptional
regulation.
Conclusions
In conclusion, our study demonstrates specific effects of
G3BP1 and G3BP2 in breast cancer cells. G3BP1, but not
G3BP2, supports proliferation and influences mRNA
levels of different genes. We identified PMP22 as a gene
that is suppressed by G3BP1 and this could be one mech-
anism that mediates the G3BP1 effect on proliferation.
Methods
Cell culture
MCF-7, MDA-MB-231, MDA-MB-468 and BT549 cell
lines were all cultured in RPMI 1640 medium (Sigma)
supplemented with 10% fetal bovine serum (EuroClone),
100 IU/ml penicillin (Gibco), and 100 μg/ml strepto-
mycin (Gibco) and 1% sodium pyruvate (Gibco). BT549
medium was additionally supplemented with 0.023 IU/ml
insulin. Cells were maintained in a humidified atmosphere
with 5% CO2 at 37°C and seeded at a density of 1.5×10
5
cells/35-mm dish or 0.5×105 cells/12-well plate. For siRNA
transfections, cells were seeded at a density of 1.2×105 cells/
35-mm dish. Actinomycin D (Sigma) was used at 4 μg/ml
when indicated and cells from three experiments were
harvested at 0, 2, 4 or 8 hours. PMP22 mRNA half-times
were calculated by doing a non-linear curve fit to the
equation y = a*2-x/b using the nls function in R.
Plasmids and transfection
Expression vectors encoding G3BP1, G3BP2a and G3BP2b
were constructed using cDNA digested from GST-
G3BP fusion vectors [23] inserted in p3xFLAG-CMV-
7.1 (Sigma). Cells were transfected in Optimem (Gibco)
with 2 μg plasmid DNA for 24 hours using Lipofectamine
2000 (Invitrogen). Transfection with 40 nM siRNA
(Stealth RNAi, Invitrogen) was performed for 72 hours
(sequences are listed in Table 2).
Western blot
Cells were lysed for 15 minutes on ice with 150 μl RIPA
buffer (10 mM Tris–HCl pH 7.2, 160 mM NaCl, 1% Tri-
ton X-100, 1% Na-deoxycholate, 0.1% SDS, 1 mM EGTA
and 1 mM EDTA) supplemented with complete protease
inhibitor cocktail without EDTA (Roche). Lysates were
cleared by centrifugation at 14000 × g for 15 min at 4°C
and sample buffer was added to the supernatant. Proteins
Table 2 siRNA nucleotides
siRNA oligonucleotide Sequence
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membrane (Millipore). Membranes were pre-incubated
with 5% dried milk in PBS followed by incubation with
primary antibodies. Membranes were washed and incu-
bated with horseradish peroxidase-labeled secondary anti-
body, which were detected with the SuperSignal system
(Biological Industries), enhanced chemiluminescence de-
tection system (GE Healthcare) or SuperSignal (Pierce).
The chemiluminescence was captured with a charge-
coupled device camera (Fujifilm). Anti-G3BP2 polyclonal
antibody has been described [23]. Antibodies against
G3BP1, FLAG and actin were purchased from BD Bio-
science, Sigma and Santa Cruz, respectively.
Proliferation assay and analysis of cell number
For the proliferation assay, cells were seeded in triplicate
at a density of 5×104 cells/well in 12-well plates and
transfected with 1 μg plasmid DNA or 40 nM siRNA
in 1 ml antibiotics-free medium for 24 or 72 hours.
Cells were incubated with 1 μCi/ml [3H]-thymidine
for 6 hours before harvesting the cells with 10 mM
EDTA. The amount of radioactivity was measured with
a Tri-carb 2810TR liquid scintillation analyzer (Perkin
Elmer). The number of viable cells was quantified follow-
ing, suspending the cells, addition of trypan blue (Sigma-
Aldrich), and counting of trypan blue-negative cells.
Annexin V-staining
Cells were detached from the dish using trypsin and
washed twice in PBS prior to Annexin V-APC staining ac-
cording to supplier’s protocol (BD, Pharmingen). 10000
events were acquired in channel FL-4 with a FACSCalibur
(Becton Dickinson). Analyses were performed with Cell-
Quest software (Becton Dickinson).
Fragmented nuclei
Cells were cultured on coverslips for 24 hours prior to
transfection with 40 nM siRNA according to standardprocedure. After 72 hours, cells were washed with PBS
and fixed with 4% paraformaldehyde in PBS for 4 mi-
nutes followed by two additional washing steps. Cover-
slips were mounted onto slides with VECTASHIELD
mounting medium containing DAPI as counterstain
(Vector Laboratories) and sealed with nail polish. For
each cover slip 200 nuclei were scored for apoptotic
morphology.Quantitative real-time PCR
Total RNA was extracted from cells using RNeasy ex-
traction kit (Qiagen). 2 μg RNA was treated with DNase
(Promega) followed by sample wash (Amicon Ultra,
Millipore) before cDNA synthesis (High capacity cDNA
RT kit, Applied Biosystems), all according to manufac-
turers’ instructions. Quantitative PCR was performed
with SYBR green master mix (Applied Biosystems) in
7300 Real-Time PCR system (Applied Biosystems),
(10 min 95°C, 40 cycles of 15 sec 95°C followed by
1 min 60°C, dissociation 60°C to 95°C). Quantifications
of expression levels were calculated by comparison of
Ct values and normalization of the relative expression
to stably expressed reference genes SDHA, YWHAZ and
UBC. Sequences are listed in Table 3.Microarray
Illumina DirectHyb HumanHT-12 v4.0 whole genome
microarray was performed at the SCIBLU facility at
Lund University. RNA was extracted from MCF-7 cells
as described above, and evaluated on a Bioanalyzer 2100
(Agilent). Microarray data were background-corrected
and normalized using the lumiB and lumiN functions
from the lumi package in R [37]. Clustering was done
using the AGNES (Agglomerative Hierarchical clustering
algorithm) function in the cluster package. Differences
in expression levels of individual genes were analyzed by
fitting to a linear model followed by ranking using an
empirical Bayes method (lmFit and eBayes functions in
the limma package of R).
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Additional file 1: Figure S1. Dendrogram chart of G3BP depleted
MCF-7 cells. Three separate experiments of MCF-7 cells with downregulated
G3BP1 (1), G3BP2 (2), G3BP1 and G3BP2 (1/2) or cells treated with control
siRNA (C) were analyzed for global gene expression. The expression data
were clustered with the AGNES function in the cluster package of R.
Additional file 2: Table S1. Differentially expressed genes. Expression
data from MCF-7 cells with downregulated G3BP1 and/or G3BP2 were
analyzed with the limma package of R. For each gene the fold change
(Log) and adjusted p-value are shown.
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